Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (261-270 of 713) with videos related to

Pageof 72
Sort By:
Leukemia & Lymphoma|March 4, 2010
Late relapses in acute myeloid leukemia: analysis of characteristics and outcomeDushyant Verma, Hagop Kantarjian, Stefan Faderl, et al.
Leukemia Research|May 10, 2006
Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cellsSrdan Verstovsek, Francis J Giles, Alfonso Quintás-Cardama, et al.
Haematologica|April 26, 2012
Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemiaAziz Nazha, Jorge Cortes, Stefan Faderl, et al.
Leukemia Research|December 25, 2007
An immunological method for the detection of BCR-ABL fusion protein and monitoring its activationIman Jilani, Hagop Kantarjian, Homan Faraji, et al.
The Lancet. Haematology|March 15, 2017
Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trialLucia Masarova, Keyur P Patel, Kate J Newberry, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2008
WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutationSrdan Verstovsek, Taghi Manshouri, Alfonso Quintás-Cardama, et al.
British Journal of Haematology|November 18, 2003
Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemiaDeborah A Thomas, Elihu Estey, Francis J Giles, et al.
Cancer|January 26, 2006
Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndromeHagop Kantarjian, Miloslav Beran, Jorge Cortes, et al.
Cancer Chemotherapy and Pharmacology|December 24, 2002
Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemiaYesid Alvarado, Apostolia Tsimberidou, Hagop Kantarjian, et al.
Pharmacoeconomics|May 26, 2007
Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemiaTheodore Darkow, Henry J Henk, Simu K Thomas, et al.
Pageof 72

Showing results (261-270 of 713) with videos related to

Sort By:
Pageof 72
Leukemia & Lymphoma|March 4, 2010
Late relapses in acute myeloid leukemia: analysis of characteristics and outcomeDushyant Verma, Hagop Kantarjian, Stefan Faderl, et al.
Leukemia Research|May 10, 2006
Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cellsSrdan Verstovsek, Francis J Giles, Alfonso Quintás-Cardama, et al.
Haematologica|April 26, 2012
Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemiaAziz Nazha, Jorge Cortes, Stefan Faderl, et al.
Leukemia Research|December 25, 2007
An immunological method for the detection of BCR-ABL fusion protein and monitoring its activationIman Jilani, Hagop Kantarjian, Homan Faraji, et al.
The Lancet. Haematology|March 15, 2017
Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trialLucia Masarova, Keyur P Patel, Kate J Newberry, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2008
WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutationSrdan Verstovsek, Taghi Manshouri, Alfonso Quintás-Cardama, et al.
British Journal of Haematology|November 18, 2003
Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemiaDeborah A Thomas, Elihu Estey, Francis J Giles, et al.
Cancer|January 26, 2006
Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndromeHagop Kantarjian, Miloslav Beran, Jorge Cortes, et al.
Cancer Chemotherapy and Pharmacology|December 24, 2002
Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemiaYesid Alvarado, Apostolia Tsimberidou, Hagop Kantarjian, et al.
Pharmacoeconomics|May 26, 2007
Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemiaTheodore Darkow, Henry J Henk, Simu K Thomas, et al.
Pageof 72